Celcuity (NASDAQ:CELC) Receives New Coverage from Analysts at SVB Leerink

SVB Leerink began coverage on shares of Celcuity (NASDAQ:CELC) in a research note published on Monday morning, Marketbeat.com reports. The firm issued an outperform rating and a $29.00 target price on the stock.

CELC has been the topic of several other reports. Needham & Company LLC decreased their target price on shares of Celcuity from $24.00 to $23.00 and set a buy rating on the stock in a research report on Friday, May 31st. Craig Hallum reiterated a buy rating and issued a $27.00 target price (up previously from $25.00) on shares of Celcuity in a report on Thursday, May 16th. Stifel Nicolaus reissued a buy rating and set a $40.00 target price on shares of Celcuity in a research report on Thursday, May 16th. Finally, HC Wainwright restated a buy rating and issued a $27.00 price target on shares of Celcuity in a research report on Thursday, May 16th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of Buy and an average price target of $29.20.

Celcuity Price Performance

NASDAQ:CELC opened at $18.69 on Monday. The company has a market capitalization of $656.02 million, a P/E ratio of -6.72 and a beta of 0.81. The business’s 50-day moving average is $16.18 and its 200 day moving average is $16.54. The company has a current ratio of 11.23, a quick ratio of 11.23 and a debt-to-equity ratio of 0.28. Celcuity has a 12 month low of $8.39 and a 12 month high of $22.19.

Celcuity (NASDAQ:CELC) last posted its earnings results on Wednesday, May 15th. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.07. On average, equities research analysts forecast that Celcuity will post -2.85 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Celcuity

Several hedge funds and other institutional investors have recently modified their holdings of the business. SG Americas Securities LLC bought a new position in Celcuity in the 4th quarter valued at $139,000. Trust Point Inc. purchased a new stake in shares of Celcuity during the fourth quarter valued at $297,000. Pale Fire Capital SE grew its holdings in shares of Celcuity by 38.4% in the fourth quarter. Pale Fire Capital SE now owns 14,409 shares of the company’s stock worth $210,000 after purchasing an additional 4,000 shares during the last quarter. Commodore Capital LP increased its stake in Celcuity by 3.6% in the 4th quarter. Commodore Capital LP now owns 1,754,704 shares of the company’s stock worth $25,566,000 after buying an additional 60,563 shares during the period. Finally, Perceptive Advisors LLC bought a new stake in Celcuity during the 4th quarter valued at about $21,583,000. 63.33% of the stock is currently owned by hedge funds and other institutional investors.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.